[ad_1]
How would COVID-19 vaccine makers adapt to variants?
By tweaking their vaccines, a process that should be easier than coming up with the original shots.
Viruses constantly mutate as they spread, and most changes aren’t significant. First-generation COVID-19 vaccines appear to be working against today’s variants, but makers already are taking steps to update their recipes if health authorities decide that’s needed.
COVID-19 vaccines by Pfizer and Moderna are made with new technology that’s easy to update. The so-called mRNA vaccines use a piece of genetic code for the spike protein that coats the coronavirus, so your immune system can learn to recognize and fight the real thing.
If a variant with a mutated spike protein crops up that the original vaccine can’t recognize, companies would swap out that piece of genetic code for a better match—if and when regulators decide that’s necessary.
Updating other COVID-19 vaccines could be more complex. The AstraZeneca vaccine, for example, uses a harmless version of a cold virus to carry that spike protein gene into the body. An update would require growing cold viruses with the updated spike gene.
The Food and Drug Administration said studies of updated COVID-19 vaccines won’t have to be as large or long as for the first generation of shots. Instead, a few hundred volunteers could receive experimental doses of a revamped vaccine and have their blood checked for signs it revved up the immune system as well as the original vaccines.
More difficult is deciding if the virus has morphed enough to modify shots.
Globally, health authorities will monitor coronavirus mutations to spot vaccine-resistant mutations. They’d also have to decide whether any revamped vaccine should protect against more than one variant.
Overall the process would be similar to what already happens with flu vaccine. Influenza viruses mutate much faster than coronaviruses, so flu shots are adjusted every year and must protect against multiple strains.
COVID-19 shots might be tweaked if variants get worse
© 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.
Citation:
How would COVID-19 vaccine makers adapt to variants? (2021, February 25)
retrieved 25 February 2021
from https://medicalxpress.com/news/2021-02-covid-vaccine-makers-variants.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
[ad_2]
Source link
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022
